Sangamo Therapeutics, Inc.
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
Last updated:
Abstract:
The present disclosure is in the field of genome engineering, particularly targeted integration of a functional SCID-related genes (e.g., IL2RG, RAG1 and/or RAG2 gene) into an IL2RG gene of a cell for provision of proteins lacking or deficient in SCID.
Status:
Grant
Type:
Utility
Filling date:
31 Oct 2017
Issue date:
1 Jun 2021